Ir a las Transacciones
Salud

Laboratorios Saval S.A. has acquired a pharmeceutical processing plant

Laboratorios Saval S.A. has acquired a pharmeceutical processing plant in Costa Rica from Laboratorios Stein S.A.

Laboratorios Saval is a Chilean company with more than 80 years of history. It began its history in Spain in the 1930s and today, has a presence in more than 14 countries. The company manufactures and distributes pharmaceuticals in the areas of infectious diseases, ophthalmology, immunology and oncology, gastroenterology, bronchopulmonary, cardiology, psychiatry and rheumatology.

Laboratorios Stein is a leading company in Latin America in the commercialization and distribution of highly complex pharmaceutical products including innovative products, biosimilars and complex generics.

Oaklins’ team in Chile acted as financial advisor to Laboratorios Saval in this transaction.

Partes

Contáctese con el equipo de la transacción

Felipe Porzio

Socio Director
Santiago, Chile
Oaklins LarrainVial

Agustin Achondo

Director
Santiago, Chile
Oaklins LarrainVial

Alberto Parot

Analista
Santiago, Chile
Oaklins LarrainVial

Transacciones relacionadas

Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.
Salud

Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.

Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.

Aprenda más
Afric Phar has been acquired by Pharma Capital
Salud

Afric Phar has been acquired by Pharma Capital

Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.

Aprenda más
Xiel Limited has been acquired by MIS Healthcare
Private Equity | Salud

Xiel Limited has been acquired by MIS Healthcare

MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.

Aprenda más